Geneva, Nov. 3 -- International Clinical Trials Registry received information related to the study (NCT07220759) titled 'Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide' on Oct. 23.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Novo Nordisk A/S
Condition:
Overweight
Obesity
Type 2 Diabetes
Intervention:
Drug: Cagrilintide
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: November 5, 2025
Target Sample Size: 330
Countries of Recruitment:
United Stat...